Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocortisone Acetate

FDA-approved product (injectable, injection), marketed as Carmol Hc, Cortef Acetate, Cortifoam and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Inflammation
  • Pruritus
  • Skin disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Hydrocortisone Acetate reaches ≥40% AI-predicted activity against MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Enterobacteriaceae Producing Extended-spectrum β-lactamases (ESBL) Decolonization Study

    NCT00826670 · start 2009-06

    Registered record
    Registry ID
    NCT00826670
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Decolonization; Placebo (Decolonization)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-06
    Completion
    2012-08
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionDecolonization; Placebo (Decolonization)
    PhasePhase 4
    Registry statusCompleted

  • Colistin and Rifampicin for MDR-Acinetobacter

    NCT01577862 · start 2008-11

    Registered record
    Registry ID
    NCT01577862
    Conditions
    Infection Due to Resistant Bacteria; Pneumonia, Ventilator-Associated; Hospital Acquired Pneumonia; Infection of Bloodstream; Infectious Disease of Abdomen
    Interventions
    Colistin; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2011-10
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection Due to Resistant Bacteria; Pneumonia, Ventilator-Associated; Hospital Acquired Pneumonia; Infection of Bloodstream +1 more
    InterventionColistin; Rifampicin
    PhasePhase 3
    Registry statusCompleted

  • Scandinavian Cystic Fibrosis Azithromycin Study

    NCT00411736 · start 2008-05

    Registered record
    Registry ID
    NCT00411736
    Conditions
    Cystic Fibrosis
    Interventions
    Study medication, azithromycin or placebo; Azithromycin or placebo tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    2014-03
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionStudy medication, azithromycin or placebo; Azithromycin or placebo tablets
    PhasePhase 4
    Registry statusCompleted

  • Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii

    NCT00645723 · start 2008-04

    Registered record
    Registry ID
    NCT00645723
    Conditions
    Cross Infection; Pneumonia, Bacterial
    Interventions
    Colistin; Colistin and saline solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2008-04
    Completion
    2011-04
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCross Infection; Pneumonia, Bacterial
    InterventionColistin; Colistin and saline solution
    PhasePhase 3
    Registry statusUnknown

  • Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement

    NCT01631968 · start 2007-09

    Registered record
    Registry ID
    NCT01631968
    Conditions
    Infection After Primary Total Knee Arthroplasty
    Interventions
    Cement without antibiotic.; Cement with erytromycin and colistin.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2012-05
    Enrolment
    2,948

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection After Primary Total Knee Arthroplasty
    InterventionCement without antibiotic.; Cement with erytromycin and colistin.
    PhaseNot applicable
    Registry statusCompleted